U.S. Markets close in 6 hrs 24 mins

ResMed Announces Complete Mobi Launch in US Markets for COPD

Zacks Equity Research

Following a successful initial launch, ResMed Inc. RMD announced a complete launch of its portable oxygen concentrator — Mobi — in the United States for chronic obstructive pulmonary disease (COPD) or other chronic diseases. The company plans to launch Mobi in other countries in 2019, after the necessary regulatory approvals.

It’s worth mentioning here that ResMed recently closed the Propeller Health buyout for $225 million. Per management, ResMed’s cloud-connected ventilators suite for people with stage III and IV COPD (including Astral, Stellar and AirCurve 10 ST-A with iVAPS new portable oxygen concentrator Mobi) is compatible with Propeller’s portfolio catering to patients with stage II and III severity levels of COPD. Thus, the buyout is expected to widen ResMed’s COPD offerings.

Market Potential

According to a report by MarketsandMarkets, the global asthma and COPD market is estimated to reach $56,507.7 million, at a CAGR of 4.2% between 2017 and 2025.

Moreover, Connected Care in ventilation can reduce costs and improve patient outcome in COPD and beyond. With COPD being the fourth most common cause of death worldwide (per a MarketsandMarkets report), we expect the buyout to boost ResMed’s growth.

ResMed’s Progress in COPD

ResMed believes that the spectrum of cloud connected respiratory care products across its portfolio will play an important role in reducing costs and improving outcome. Connected Care in ventilation can reduce costs and improve patient outcomes in COPD and beyond.

In May, the company announced positive data from two clinical analyses conducted for the U.K. and the United States. The results supported the cost efficiency of combining home oxygen therapy and home non-invasive ventilation therapy for patients with persistent hypercapnia following a life-threatening exacerbation of COPD.

In the fiscal first quarter, the company re-launched the portable oxygen concentrator called Activox.

Price Performance

In the past three months, shares of ResMed have outperformed the industry. Per the latest price movement, the stock has risen 10% against the industry’s decline of 10.7%.

Zacks Rank & Key Picks

ResMed carries a Zacks Rank #3 (Hold) at present.

Some better-ranked stocks in the broader medical space are Veeva Systems VEEV, Surmodics, Inc. SRDX and athenahealth, Inc. ATHN.

Veeva Systems’ long-term earnings growth rate is estimated at 19.5%. The stock flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Surmodics’ long-term earnings growth rate is projected at 10%. The stock carries a Zacks Rank of 2 (Buy).

athenahealth’s long-term earnings growth rate is projected at 17.7%. The stock carries a Zacks Rank of 2.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Veeva Systems Inc. (VEEV) : Free Stock Analysis Report
athenahealth, Inc. (ATHN) : Free Stock Analysis Report
ResMed Inc. (RMD) : Free Stock Analysis Report
Surmodics, Inc. (SRDX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research